Cohance Lifesciences Ltd.
NSE: COHANCE | BSE: 543064
₹428.35
₹0.30
(0.07%)
As on 19-May-2026 15:51IST
Market cap
₹16,183 Cr
Revenue (TTM)
₹2,269 Cr
P/E Ratio
90.3
P/B Ratio
4.1
Div. Yield
0 %
Quality Score
8/10
Growth Score
4/10
Valuation Score
3/10
Momentum Score
1/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹179 Cr
-
ROE
14.2 %
-
ROCE
18.4 %
-
Industry P/E
59.42
-
EV/EBITDA
35.3
-
Debt to Equity
0
-
Book Value
₹102.2
-
EPS
₹5.4
-
Face value
1
-
Shares outstanding
382,567,140
7 Years Aggregate
CFO
₹2,299.99 Cr
EBITDA
₹2,936.21 Cr
Net Profit
₹2,218.76 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cohance Lifesciences
| -19.0 | 9.7 | 31.5 | -60.3 | -3.4 | -4.4 | -- |
|
BSE Healthcare
| 9.5 | 9.4 | 9.8 | 12.1 | 27.6 | 14.5 | 11.8 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
| -52.9 | 58.1 | 46.0 | 0.3 | 6.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cohance Lifesciences
|
428.4 | 16,182.6 | 2,268.6 | 150.1 | 10.6 | 5.4 | 90.3 | 4.1 |
| 2,886.5 | 23,628.0 | 1,339.4 | 356.4 | 33.2 | 23.2 | 66.3 | 14.3 | |
| 766.5 | 18,625.7 | 5,365.6 | 595.0 | 16.6 | 13.3 | 31.3 | 3.7 | |
| 1,011.0 | 16,340.7 | 7,918.4 | 429.9 | 10.7 | 7.2 | 37.8 | 2.5 | |
| 1,130.9 | 20,485.7 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 13.2 | 2.3 | |
| 1,854.5 | 21,358.5 | 1,421.6 | -73.8 | 1.8 | -1.1 | -- | 3.7 | |
| 173.2 | 23,055.8 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.8 | |
| 984.5 | 16,197.2 | 1,284.3 | 134.4 | -- | 30.7 | 120.5 | 13.3 | |
| 471.4 | 19,226.8 | 3,738.7 | 316.7 | 12.5 | 7.5 | 60.7 | 4.0 | |
| 1,620.2 | 25,953.3 | 3,373.0 | 199.0 | 12.6 | 5.9 | 121.8 | 5.3 |
Shareholding Pattern
View DetailsNews & Analysis
All News
Two pharmaceutical giants announce merger
2 min read•By Satyajit Sen
About Cohance Lifesciences
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United... States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited. Read more
-
Incorporated
2018
-
Chairman
--
-
Managing Director
--
-
Headquarters
Mumbai, Maharashtra
-
Website
Looking for more details about Cohance Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
FAQs for Cohance Lifesciences
What is the current share price of Cohance Lifesciences Ltd Today?
The share price of Cohance Lifesciences Ltd is ₹428.35 (NSE) and ₹429.45 (BSE) as of 19-May-2026 15:51 IST. Cohance Lifesciences Ltd has given a return of -3.39% in the last 3 years.
What is the current PB & PE ratio of Cohance Lifesciences Ltd?
The P/E ratio of Cohance Lifesciences Ltd is 90.29 times as on 19-May-2026, a 52 premium to its peers’ median range of 59.42 times.
The P/B ratio of Cohance Lifesciences Ltd is 4.14 times as on 19-May-2026, a 16 premium to its peers’ median range of 3.56 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
110.23
|
17.58
|
|
2024
|
57.37
|
8.41
|
|
2023
|
29.26
|
6.93
|
|
2022
|
34.66
|
10.30
|
|
2021
|
34.80
|
10.68
|
What is the 52 Week High and Low of Cohance Lifesciences Ltd?
The 52-week high and low of Cohance Lifesciences Ltd are Rs 1,121.15 and Rs 266.70 as of 19-May-2026.
What is the market cap of Cohance Lifesciences Ltd?
Cohance Lifesciences Ltd has a market capitalisation of ₹ 16,183 Cr as on 19-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cohance Lifesciences Ltd?
Before investing in Cohance Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.